Werewolf Therapeutics, Inc. Logo

Werewolf Therapeutics, Inc.

Developing tumor-activated immunotherapies for a localized immune attack on cancer.

HOWL | US

Overview

Corporate Details

ISIN(s):
US95075A1079
LEI:
Country:
United States of America
Address:
200 TALCOTT AVENUE, 2472 WATERTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company's approach addresses the limitations of conventional immunotherapy, such as off-target side effects, by utilizing its proprietary PREDATOR™ protein engineering platform. This technology is used to create conditionally activated proinflammatory immune modulators, called INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become fully active only within the tumor microenvironment. This targeted mechanism aims to unleash a potent, localized immune attack on cancer cells while minimizing damage to healthy tissue.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:11
Quarterly Report
10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)
English 1.6 MB
2025-11-04 13:07
Regulatory News Service
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
English 569.0 KB

Automate Your Workflow. Get a real-time feed of all Werewolf Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Werewolf Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Werewolf Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CRESCENT BIOPHARMA, INC. Logo
A biotech company developing bispecific antibody therapies to treat solid tumors.
United States of America
CBIO
Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan
4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America
CUPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.